Cargando…

Epigenetic modulations in cancer: predictive biomarkers and potential targets for overcoming the resistance to topoisomerase I inhibitors

INTRODUCTION: Altered epigenetic map is frequently observed in cancer and recent investigations have demonstrated a pertinent role of epigenetic modifications in the response to many anticancer drugs including the DNA damaging agents. Topoisomerase I (Top I) is a well-known nuclear enzyme that is cr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Madkour, Moustafa M., Ramadan, Wafaa S., Saleh, Ekram, El-Awady, Raafat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10128461/ https://www.ncbi.nlm.nih.gov/pubmed/37092854 http://dx.doi.org/10.1080/07853890.2023.2203946

Ejemplares similares

Effect of safranal on the response of cancer cells to topoisomerase I inhibitors: Does sequence matter?
por: Lozon, Lama, et al.
Publicado: (2022)

The Role of HDACs in the Response of Cancer Cells to Cellular Stress and the Potential for Therapeutic Intervention
por: Alseksek, Rahma K., et al.
Publicado: (2022)

Interplay between Epigenetics, Expression of Estrogen Receptor- α, HER2/ERBB2 and Sensitivity of Triple Negative Breast Cancer Cells to Hormonal Therapy
por: Ramadan, Wafaa S, et al.
Publicado: (2018)

Recent advances in management of COVID-19: A review
por: Mouffak, Soraya, et al.
Publicado: (2021)

Epigenetic changes in histone acetylation underpin resistance to the topoisomerase I inhibitor irinotecan
por: Meisenberg, Cornelia, et al.
Publicado: (2017)

Discovery of New Catalytic Topoisomerase II Inhibitors for Anticancer Therapeutics
por: Matias-Barrios, Victor M., et al.
Publicado: (2021)

The Role of Eukaryotic and Prokaryotic ABC Transporter Family in Failure of Chemotherapy
por: El-Awady, Raafat, et al.
Publicado: (2017)

The impact of CBP expression in estrogen receptor-positive breast cancer
por: Ramadan, Wafaa S., et al.
Publicado: (2021)

Reversing Epigenetic Gene Silencing to Overcome Immune Evasion in CNS Malignancies
por: Ratnam, Nivedita M., et al.
Publicado: (2021)

Investigating the Anticancer Potential of Salvicine as a Modulator of Topoisomerase II and ROS Signaling Cascade
por: Dey, Dipta, et al.
Publicado: (2022)

Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities
por: Xie, Qingqing, et al.
Publicado: (2022)

Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets
por: Gilbert, D C, et al.
Publicado: (2012)

Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas
por: dos Santos, Lucas V., et al.
Publicado: (2021)

Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer
por: Cheng, Chao, et al.
Publicado: (2022)

Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus
por: Sciammarella, Concetta, et al.
Publicado: (2020)

Concurrent inhibition of FAK/SRC and MEK overcomes MEK inhibitor resistance in Neurofibromatosis Type I related malignant peripheral nerve sheath tumors
por: Gu, Yihui, et al.
Publicado: (2022)

Discoidin Domain Receptors in Melanoma: Potential Therapeutic Targets to Overcome MAPK Inhibitor Resistance
por: Reger de Moura, Coralie, et al.
Publicado: (2020)

Identification of Schlafen-11 as a Target of CD47 Signaling That Regulates Sensitivity to Ionizing Radiation and Topoisomerase Inhibitors
por: Kaur, Sukhbir, et al.
Publicado: (2019)

Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors
por: Irabor, Omoruyi Credit, et al.
Publicado: (2022)

Overcoming Resistance to Checkpoint Inhibitors: Natural Killer Cells in Non-Small Cell Lung Cancer
por: Gemelli, Maria, et al.
Publicado: (2022)

Epigenetic modulation in sensitizing metastatic sarcomas to therapies and overcoming resistance
por: Rytlewski, Jeff, et al.
Publicado: (2022)

Novel bivalent securinine mimetics as topoisomerase I inhibitors
por: Hou, Wen, et al.
Publicado: (2017)

Small DNA circles as bacterial topoisomerase I inhibitors
por: Li, Dawei, et al.
Publicado: (2019)

Epigenetic Alterations and Biomarkers for Immune Checkpoint Inhibitors–Current Standards and Future Perspectives in Malignant Pleural Mesothelioma Treatment
por: Yoshikawa, Yoshie, et al.
Publicado: (2020)

Targeting O-GlcNAcylation to overcome resistance to anti-cancer therapies
por: Very, Ninon, et al.
Publicado: (2022)

The modulation of topoisomerase I-mediated DNA cleavage and the induction of DNA–topoisomerase I crosslinks by crotonaldehyde-derived DNA adducts
por: Dexheimer, Thomas S., et al.
Publicado: (2008)

Overcoming Limitations of Cisplatin Therapy by Additional Treatment With the HSP90 Inhibitor Onalespib
por: Mortensen, Anja Charlotte Lundgren, et al.
Publicado: (2020)

A Novel Copper(II) Indenoisoquinoline Complex Inhibits Topoisomerase I, Induces G2 Phase Arrest, and Autophagy in Three Adenocarcinomas
por: Molinaro, Caroline, et al.
Publicado: (2022)

Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.
por: Ando, M., et al.
Publicado: (1997)

Immunotherapy and Epigenetic Pathway Modulation in Glioblastoma Multiforme
por: Chin, Christopher, et al.
Publicado: (2018)

Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance
por: Mahfoudhi, Emna, et al.
Publicado: (2022)

Co-administration of MDR1 and BCRP or EGFR/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma
por: Sun, Dawei, et al.
Publicado: (2022)

Novel Thiazolidine-2,4-dione-trimethoxybenzene-thiazole Hybrids as Human Topoisomerases Inhibitors
por: Sinicropi, Maria Stefania, et al.
Publicado: (2023)

Epigenetic Enzyme Mutations: Role in Tumorigenesis and Molecular Inhibitors
por: Han, Mei, et al.
Publicado: (2019)

Phosphodiesterase Type 5 (PDE5) Inhibitors Sensitize Topoisomerase II Inhibitors in Killing Prostate Cancer Through PDE5-Independent Impairment of HR and NHEJ DNA Repair Systems
por: Chang, Jo-Fan, et al.
Publicado: (2019)

FGFR inhibitors combined with nab-paclitaxel - A promising strategy to treat non-small cell lung cancer and overcome resistance
por: Ma, Feng, et al.
Publicado: (2023)

Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer
por: Vander Ark, Alexandra, et al.
Publicado: (2018)

Overcoming the therapeutic resistance of hepatomas by targeting the tumor microenvironment
por: Zhang, Jiaxin, et al.
Publicado: (2022)

Editorial: Overcoming drug relapse and therapy resistance in NSCLC
por: Parakh, Sagun, et al.
Publicado: (2023)

A new approach to overcoming resistance to immunotherapy: nanotechnology
por: Shao, Jiangbo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2tr22jn0md4g7q8389ndido34l